Caretek secures big pharma partner
Oxford-based Caretek Medical has now also secured the support of a
major global pharma company to help Caretek run a feasibility study
on its innovative needle-free drug delivery system.
>Caretek will now run lab tests to determine whether its ImplaJect device can inject a solid dose of one of the pharmaceutical company's protein based drugs, that is currently given to patients in liquid via needle and syringe.
ImplaJect is the size of a fountain pen and uses a spring mechanism to push solid drugs through the skin into the underlying tissue where they dissolve and are released into the patient's bloodstream.
The device could provide a user-friendly way for tens of thousands of patients to receive protein-based drugs.
"Given the choice, patients would prefer to receive drugs in an oral tablet form but many drugs, such as insulin, vaccines and emergency medicines, cannot be administered by mouth because they will not be adequately absorbed in the body or act quickly enough," said Dr Charles Potter, Caretek's founder and CEO.
Similar devices are available on the market and used to deliver drugs such as insulin, however, these systems use a liquid form of the drug as opposed to the ImplaJect, which is unique in using a solid form.
"The ImplaJect system has the potential to generate substantial cost savings by eliminating the need to make arrangements for refrigerated storage of liquid drugs," said Potter.
"In addition, 15 billion needles are used worldwide every year and the ImplaJect could help to reduce the major burden of needle disposal," he said.
Furthermore, the device could also benefit healthcare staff who currently suffer an estimated at 600,000 to 800,000 needle stick injuries annually, risking serious infection.
The company expects the feasibility study to take four months and are hoping a positive result will lead to the commercial development of the study drug in a solid form, for use within the ImplaJect system.
